NCT00585221 - Study of Imatinib and Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions

Gastrointestinal Stromal TumorsCancer BrainSolid Tumors

Interventions

DRUG

Peginterferon-alpha 2b (PegIFNa2b);

Treatment include PegIFNa2b high dose (3 mcg/kg/wk) X 4 doses and low dose (1.5 mcg/kg/wk) X 18 doses, followed by surgical evaluation to render pt disease free if possible.

DRUG

Imatinib

Continue imatinib until progression.

Trial Locations (1)

84112

University of Utah, Salt Lake City